Technology

Cambridge CARES continues decade-long collaboration with Singapore universities with two decarbonisation projects

Published

1 year ago

December 5, 2024

The University of Cambridge’s first overseas research centre (CARES) hosted Mr Heng Swee Keat, Deputy Prime Minister and Chairman of the National Research Foundation (NRF) to view the centre’s technical capabilities for decarbonisation research.Local and international partners will advance research on non-fossil fuel-based pathways for Singapore industries.

SINGAPORE, Dec. 5, 2024 /PRNewswire/ — The Cambridge Centre for Advanced Research and Education in Singapore (CARES) is hosting two projects under the newly launched CREATE Thematic Programme in Decarbonisation supported by the National Research Foundation (NRF). The two projects will investigate non-fossil fuel-based pathways for Singapore’s chemical manufacturing industry and energy systems. The projects will advance new technology and ideas from existing work at CARES and aid in Singapore’s business transition away from petrochemicals towards a net-zero emissions target by 2050.

Deputy Prime Minister and Chairman of the NRF, Mr Heng Swee Keat toured the first of three laboratories for the programme to view the technical capabilities required for the various project teams, including CARES’ projects on the Sustainable Manufacture of Molecules and Materials in Singapore (SM3), and Hydrogen and Ammonia Combustion in Singapore (HYCOMBS).

As part of the lab demonstrations on decarbonisation, CARES showcased an additional ongoing activity with City Energy investigating hydrogen-rich town gas for residential and commercial cooking stoves.

Prof. Alexei Lapkin (CARES), Prof. Chiba Shunsuke (NTU Singapore), Prof. Ning Yan (NUS), Assoc Prof. Ming Joo Koh (NUS), Dr. Philippe Schwaller (Swiss Federal Institute of Technology Lausanne, EPFL), and Prof. Matthew Gaunt (University of Cambridge), Principal Investigators for SM3, share a joint statement:

SM3 will provide a path to a net-zero, high-value chemical manufacturing industry in Singapore. Its core goal is to address the dependency of the producers of performance chemicals on starting materials that typically come from fossil-based carbon sources. The SM3 team will develop effective synthetic methods that best convert cheap and abundant fossil-free raw materials into high-value molecules. SM3 will transform the production of functional molecules, such as medicines and agrochemicals, creating a new value chain for the sustainable chemical industry.

Prof. Epaminondas Mastorakos (CARES), Prof. Fei Duan (NTU Singapore), Prof. Kaoru Maruta (Tohoku University), Dr Nabiha Chaumeix (CNRS France), Asst Prof Zhang Huangwei (NUS), Principal Investigators for HYCOMBS, share a joint statement:

In the near future, Singapore may adopt hydrogen or ammonia as a possible carbon-free fuel for decarbonisation; however, this requires the development of new gas turbines and internal combustion engines. In project HYCOMBS, universities from Singapore, UK, Japan, France and Norway will work together to investigate the underlying combustion process of hydrogen and ammonia to minimise pollutants and accelerate industry innovation. We are grateful for the opportunity to work on this project that can transform how these zero-carbon fuels are utilised, benefiting Singaporeans and global environmental advancement.

Since 2013, CARES has been involved in research programmes with NTU and NUS as the University of Cambridge’s first overseas centre. One of its early flagship programmes, the Centre for Carbon Reduction in Chemical Technologies (C4T), has investigated areas from sustainable reaction engineering, electrochemistry, and maritime decarbonisation, to digitalisation.

By building on this foundation and leveraging the local talent pool, CARES has attracted new partners from international universities and institutes for SM3 and HYCOMBS. This includes EPFL, the Swiss Federal Institute of Technology Lausanne, which will provide skills in the domain AI for chemistry. CNRS, the French National Centre for Scientific Research, from France, the Norwegian University of Science and Technology, and Tohoku University from Japan will contribute technical equipment and key talent in hydrogen and ammonia combustion. The connection with CNRS will be further strengthened through the presence in Singapore of CNRS@CREATE – its only subsidiary abroad – which is part of the same CREATE research programme that CARES participates in.

Singapore’s compact, interconnected infrastructure, along with strong governmental support and initiatives such as the “Singapore Green Plan 2030” will provide an ideal base for rapid testing and knowledge transfer to industry. The international scope of SM3 and HYCOMBS positions Singapore as a central hub for sustainable technology development for the global economy.

View the media release by NRF on the launch of the SGD$90m Decarbonisation programme for more information on the nine projects under CREATE’s Decarbonisation Programme.

Annex A: Full list of PIs and their affiliated universities and/or institutions

About CARES

The Cambridge Centre for Advanced Research and Education (CARES) was established in 2013 as the University of Cambridge’s first overseas research centre, bringing together researchers from Cambridge, Nanyang Technological University, and the National University of Singapore as part of the CREATE (Campus for Research Excellence and Technological Enterprise) programme. The flagship programme at CARES is the Centre for Carbon Reduction in Chemical Technology (C4T) programme which focused on decarbonising Singapore’s chemical industry and expanded in recent years to include additional themes such as digital transformation, and sectors such as the maritime industry.

A further large programme began in October 2020 called the Centre for Lifelong Learning and Individualised Cognition (CLIC). CLIC brings together researchers from the University of Cambridge and NTU to focus on the science of learning. CARES is also a research partner in the Pharmaceutical Innovation Programme Singapore (PIPS), a public-private consortium that aims to develop full process automation in a laboratory to support R&D and manufacturing.

www.cares.cam.ac.uk LinkedIn: Cambridge CARES

About CREATE (Campus for Research Excellence and Technological Enterprise)

CREATE is an international collaboratory housing research centres set up by top universities. At CREATE, researchers from diverse disciplines and backgrounds work closely together to perform cutting-edge research in strategic areas of interest, for translation into practical applications leading to positive economic and societal outcomes for Singapore. The interdisciplinary research centres at CREATE focus on four areas of interdisciplinary thematic areas of research, namely human systems, energy systems, environmental systems and urban systems.

More information on the CREATE programme can be obtained from www.create.edu.sg.

Annex A: Full list of PIs and their affiliated universities and/or institutions

Sustainable Manufacture of Molecules and Materials in Singapore (SM3)

Prof. Alexei LAPKIN (University of Cambridge), Prof. Shunsuke CHIBA (Nanyang
Technological University, Singapore), Prof. Ning YAN (National University of Singapore),
and Assoc Prof. Ming Joo KOH (National University of Singapore) are the Programme
Leads.

All other Principal Investigators are listed in alphabetical order with their universities and/or
institutions:

• Asst Prof. Tej Salil CHOKSI (Nanyang Technological University)

• Prof. Matthew GAUNT (University of Cambridge)

• Prof. Saif KHAN (National University of Singapore)

• Dr. Ewa MAREK (University of Cambridge)

• Asst Prof. Philippe SCHWALLER (Swiss Federal Institute of Technology Lausanne)

Webpage: https://www.cares.cam.ac.uk/research/sm3/

Hydrogen and Ammonia Combustion in Singapore (HYCOMBS)

Prof. Epaminondas MASTORAKOS (University of Cambridge), Assoc Prof. Fei DUAN
(Nanyang Technological University, Singapore), and Prof. Kaoru MARUTA (Tohoku
University) are the Programme Leads.

All other Principal Investigators are listed in alphabetical order with their universities and/or
institutions:

• Prof. Siew Hwa CHAN (Nanyang Technological University)

• Dr. Nabiha CHAUMEIX (Centre Nationale de la Recherche Scientifique)

• Dr. Sebastian DUCRUIX (Centre Nationale de la Recherche Scientifique)

• Assoc Prof. Akihiro HAYAKAWA (Tohoku University)

• Prof. Nicholas MINESI (Centre Nationale de la Recherche Scientifique)

• Asst Prof. Youhi MORII (Tohoku University)

• Prof. Hisashi NAKAMURA (Tohoku University)

• Prof. Christine ROUSSELLE (Centre Nationale de la Recherche Scientifique)

• Prof. Nedunchezhian SWAMINATHAN (University of Cambridge)

• Prof. Nicholas WORTH (Norwegian University of Science and Technology)

• Asst Prof. Huangwei ZHANG (National University of Singapore)

Webpage: https://www.cares.cam.ac.uk/research/hycombs/

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cambridge-cares-continues-decade-long-collaboration-with-singapore-universities-with-two-decarbonisation-projects-302323319.html

SOURCE Cambridge Centre for Advanced Research and Education in Singapore

Technology

Baidu to Report First Quarter 2026 Financial Results on May 18, 2026

Published

54 minutes ago

April 23, 2026

BEIJING, April 23, 2026 /PRNewswire/ — Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) (“Baidu” or the “Company”), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2026 ended March 31, 2026, before the U.S. market opens on May 18, 2026. Baidu’s management will hold an earnings conference call at 8:00 AM on May 18, 2026, U.S. Eastern Time (8:00 PM on May 18, 2026, Beijing Time).

Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of “Baidu Inc. Q1 2026 Earnings Conference Call”. Please follow the steps to enter your registration details, then click “Register”. Upon registering, you will then be provided with the dial-in number, the passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

For pre-registration, please click:
https://s1.c-conf.com/diamondpass/10054331-iu876y.html

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), the passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

Additionally, a live and archived webcast of this conference call will be available at https://ir.baidu.com.

A replay of the conference call may be accessed by phone at the following number until May 25, 2026:
US: 1 855 883 1031
Reply PIN: 10054331

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under “BIDU” and the HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

View original content:https://www.prnewswire.com/news-releases/baidu-to-report-first-quarter-2026-financial-results-on-may-18-2026-302751204.html

SOURCE Baidu, Inc.

Technology

Phase 1 of 139th Canton Fair Introduces New Dedicated Product Zones as Emerging Technologies Take Center Stage

Published

54 minutes ago

April 23, 2026

GUANGZHOU, China, April 23, 2026 /PRNewswire/ — The 139th China Import and Export Fair (Canton Fair) has further optimized its exhibition landscape with nine new dedicated product zones, reflecting ongoing structural shifts in global trade and the continued upgrading of China’s export portfolio.

Among the most closely watched additions in Phase 1 are the consumer and agricultural drone zones, both making their debut at the Canton Fair and offering a focused showcase of applications in the low‑altitude economy. The consumer drone zone showcases progress in flight control, AI‑based obstacle avoidance and energy efficiency across imaging, tourism, emergency response and patrol. The agricultural drone zone highlights precision farming, with spraying, seeding and field‑management demonstrations showing terrain‑following, intelligent route planning, and precise payload control.

On day one, a Shandong‑based drone manufacturer welcomed buyers from 30+ countries, with over 50 strong leads. One buyer, after seeing load and wind‑resistance demonstrations, immediately confirmed three sample units and even proposed becoming a regional distributor.

Display technology is another focal point of Phase 1, highlighting advances in color accuracy, energy efficiency, and overall visual performance. Developments in fine‑grained control, expanded color gamut, and reduced power consumption point to a clear trend toward immersive viewing experiences combined with sustainability gains.

The smart wearables zone underscores how intelligent devices are becoming key interfaces for human‑machine interaction. From real‑time language translation and adaptive noise cancellation to long‑term health monitoring and AI‑enabled eyewear, wearables are evolving from standalone products into integrated systems that support communication, well‑being, and productivity across daily and professional settings.

The service robots zone further illustrates how artificial intelligence is moving from conceptual exploration to large‑scale deployment. Advanced robots showcased across industrial, commercial, medical, and public‑service scenarios demonstrate growing autonomy, multi‑sensory perception, and closer human-robot collaboration.

By bringing emerging technologies into clearer focus through dedicated zones, the 139th Canton Fair is reinforcing its function as a platform where trade trends take shape, innovation meets application, and global buyers gain early insights into cutting-edge technologies.

For pre-registration, please click: https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Photo – https://mma.prnewswire.com/media/2963958/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/phase-1-of-139th-canton-fair-introduces-new-dedicated-product-zones-as-emerging-technologies-take-center-stage-302751520.html

Technology

OZMOSI Announces Strategic Partnership with Planview to Advance AI-Driven Planning in Pharmaceutical R&D

Published

54 minutes ago

April 23, 2026

By combining structured clinical intelligence with AI-driven portfolio planning, the partnership gives pharmaceutical teams a faster, clearer way to make high-stakes R&D decisions

SPRING LAKE HEIGHTS, N.J., April 23, 2026 /PRNewswire/ — OZMOSI, a leading provider of structured pharmaceutical development intelligence, today announced a strategic partnership with Planview, the leading AI-powered end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD).

By integrating OZMOSI’s machine-readable clinical datasets directly into Planview’s AI-driven portfolio planning platform, external scientific data is now connected to internal R&D planning in one system, helping pharmaceutical organizations better predict market shifts, prioritize R&D investments, and make faster, more confident decisions.

This integration brings external clinical reality into internal R&D decision-making, so teams can plan based on what’s actually happening, not just on what they hope will happen.

The two organizations combine deep expertise in complementary areas, united by a shared focus on improving the quality and usability of data for strategic decision-making. OZMOSI provides structured, machine-readable intelligence across clinical trials, drug development programs, regulatory activity, and scientific literature, built on a consistent taxonomy that standardizes how data is connected and understood. Planview’s platform enables organizations to model complex investment scenarios, align initiatives with corporate strategy, and optimize resource allocation.

Together, these capabilities give teams a clearer, more complete view of the R&D landscape, grounded in clean, standardized data and strengthened by AI-driven analysis.

“AI is only as powerful as the data that fuels it,” said Beau Bush, President and Founder of OZMOSI. “Pharmaceutical organizations have no shortage of data, but too often it’s fragmented, inconsistent, and difficult to operationalize. By bringing OZMOSI’s structured data foundation together with Planview’s AI-driven planning capabilities, we’re enabling teams to move beyond disconnected analysis and toward truly integrated, forward-looking decision-making.”

“Strategic planning in pharmaceutical R&D is becoming increasingly dependent on advanced analytics and AI,” said Louise Allen, Chief Product Officer at Planview. “Integrating OZMOSI’s clinical intelligence into Planview’s platform enables pharmaceutical leaders to make better decisions by combining trusted external data with AI-driven planning

OZMOSI’s dataset spans more than 800,000 clinical trials, over 35,000 drugs, and 4,000 diseases and conditions. It brings together insights from clinical trial registries, regulatory filings, scientific literature, company disclosures, and industry announcements into a unified, structured dataset.

When integrated into Planview’s platform, this intelligence enables pharmaceutical and biotech organizations to evaluate competitive landscapes, identify emerging clinical trends, and simulate portfolio outcomes with unprecedented precision.

Together, OZMOSI and Planview are redefining how pharmaceutical organizations approach R&D strategy, ensuring that investment decisions are guided by accurate, standardized, and AI-ready data. By combining internal portfolio visibility with a continuously updated external view of the market, the partnership helps leaders not only understand what they have, but what to do next.

About OZMOSI

Founded in 2013, OZMOSI specializes in transforming complex pharmaceutical R&D intelligence into structured, machine-readable data. The company provides the foundation needed for accurate competitive analysis, product forecasting, and portfolio strategy. Through its proprietary taxonomy and semantic layer, OZMOSI connects fragmented data across the pharmaceutical ecosystem, enabling faster, more confident decision-making for global pharma, biotech, and investment teams.

Based in Spring Lake Heights, New Jersey, OZMOSI is focused on making pharmaceutical intelligence clear, usable, and ready for the future of AI-driven strategy. Learn more at www.ozmosi.com.

About Planview

Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD), powered by advanced AI capabilities that give business and technology leaders the strategic foresight to prioritize investments and initiatives, make plans real within constraints, and pivot with certainty when things change. Our AI-driven connected platform of solutions underpins the business and digital transformations of more than 3,000 customers and 3.1 million users globally. Headquartered in Austin, Texas, Planview has over 1,500 employees worldwide. Learn more at www.planview.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ozmosi-announces-strategic-partnership-with-planview-to-advance-ai-driven-planning-in-pharmaceutical-rd-302750944.html

SOURCE Ozmosi Company